{"created":"2023-06-19T08:46:20.252259+00:00","id":1839,"links":{},"metadata":{"_buckets":{"deposit":"903965c1-ce33-4bf8-8314-ac057eb0f9fe"},"_deposit":{"created_by":25,"id":"1839","owners":[25],"pid":{"revision_id":0,"type":"depid","value":"1839"},"status":"published"},"_oai":{"id":"oai:ycu.repo.nii.ac.jp:00001839","sets":["4:71:396:401"]},"author_link":["3426","3429","3428","3423","3424","3425","3430","3421","3422","3427","3431"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-05-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"99","bibliographicPageStart":"95","bibliographicVolumeNumber":"70","bibliographic_titles":[{"bibliographic_title":"横浜医学"},{"bibliographic_title":"Yokohama Medical Journal","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"現在，川崎病の標準治療は大量ガンマグロブリン静注（IVIG; intravenous immune　globulin） 療法とされている．2018年2月にポリエチレングリコール処理人免疫グロブリンの添付文書が改訂さ れ，最大投与速度が0.03 ml/kg/minから0.06 ml/kg/minに変更された．当院においても2018年4月か ら最大投与速度をこれまでの0.03ml/kg/min から0.06ml/kg/minへ変更した．投与速度上昇に伴い1 回あたりのIVIG投与時間が短縮れ，解熱までの病日が短縮されることやIVIG不応例に対しより早い追加治療ができる可能性が考えられた．今回，診療録をもとに最大投与速度0.03ml/kg/min群（A群）43例と0.06ml/kg/min群（B群）17例について後方視的に比較検討した．両群間で性別，月齢，重症度に差はなかった．1回のIVIG療法で解熱が得られたのは，A群28例，B群15例，2回のIVIG療法 を要したのはA群7例，B群2例であった．IVIG療法のみでは解熱せず追加治療のため高次医療機関 に転院となった例はA群では8例あったものの，B群では1例も認めなかった．いずれの項目も統計学上の有意差はなかった．今回の検討では，症例数が少ないため有意差が得られなかった可能性があり，今後症例数を重ねて再検討する余地があると考えられた．","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"横浜市立大学医学会"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0372-7726","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小野瀬, 祐太"},{"creatorName":"オノセ, ユウタ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"涌井, 直人"},{"creatorName":"ワクイ, ナオト","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"長崎, 翔"},{"creatorName":"ナガサキ, ショウ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"早川, 達也"},{"creatorName":"ハヤカワ, タツヤ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"横田, 望美"},{"creatorName":"ヨコタ, ノゾミ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"玉那覇, 瑛太"},{"creatorName":"タマナハ, エイタ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"窪田, 祥平"},{"creatorName":"クボタ, ショウヘイ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"和田, 芳雅"},{"creatorName":"ワダ, ヨシマサ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"早野, 聡子"},{"creatorName":"ハヤノ, サトコ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"只木, 弘美"},{"creatorName":"タダキ, ヒロミ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"粟生, 耕太"},{"creatorName":"アオ, コウタ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-09-08"}],"displaytype":"detail","filename":"01_Onose.pdf","filesize":[{"value":"830.3 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"横浜医学70巻2号（小野瀬　祐太）","url":"https://ycu.repo.nii.ac.jp/record/1839/files/01_Onose.pdf"},"version_id":"8714b6c7-d213-4de9-b4e0-ccafd16d8b3a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"川崎病｜ガンマグロブリン療法｜ ポリエチレングリコール処理人免疫グロブリン｜投与速度","subitem_subject_scheme":"Other"},{"subitem_subject":"Kawasaki disease｜gamma-globulin therapy｜polyethylene glycol treated human normal immunoglobulin｜administration rate","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"当院での川崎病治療における大量ガンマグロブリン療法の 投与速度に関する検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"当院での川崎病治療における大量ガンマグロブリン療法の 投与速度に関する検討"},{"subitem_title":"ANALYSIS OF THE RATE OF INTRAVENOUS IMMUNE GLOBULIN  ADMINISTRATION FOR KAWASAKI DISEASE","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"25","path":["401"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-09-10"},"publish_date":"2019-09-10","publish_status":"0","recid":"1839","relation_version_is_last":true,"title":["当院での川崎病治療における大量ガンマグロブリン療法の 投与速度に関する検討"],"weko_creator_id":"25","weko_shared_id":-1},"updated":"2023-06-19T09:32:23.140362+00:00"}